By Marc Gilman
Questions?
Call (800) 927-9326 or email
Key Takeaways
-
October 22, 2026 is a real, confirmed compliance date from a U.S. Customs and Border Protection rule — but it’s a general customs and tariff rule, not a Canadian-pharmacy-specific or prescription-drug-specific ban.
-
Prescription drugs are affected because the FDA counts as a “Partner Government Agency” under the rule. Mail shipments regulated by an outside agency like the FDA now require formal customs entry — a licensed broker and a bond — instead of the simpler process most low-value mail has used.
-
CBP created an alternative pathway specifically for this kind of shipment. A new electronic “Entry Type 13” process, which began September 22, 2026, lets an eligible shipment file informally rather than going through full formal entry — still requiring a bond, but a lighter compliance path than the alternative.
-
Canadian and international pharmacies are warning customers of serious disruption, and that warning should be taken seriously — they have direct operational exposure to the new process. But it’s their business assessment of the impact, not a government announcement that shipments will be blocked outright.
-
FDA’s underlying rules on personal drug importation haven’t changed. Importing an unapproved foreign drug for personal use was already restricted and discretionary before this rule — price being lower abroad was never, by itself, a legal basis for importing.
What’s Actually Changing
On June 24, 2026, U.S. Customs and Border Protection published a rule suspending the “de minimis” exemption that let low-value international mail (generally under $800) pass through customs with minimal scrutiny. The rule is broad — aimed at revenue collection and blocking illicit shipments including fentanyl — and applies to international mail generally, not specifically to medications or to Canada.
The piece that affects prescription imports is one specific provision: mail shipments subject to another federal agency’s requirements — and the FDA regulates imported human drugs — must go through formal customs entry rather than the simpler process available to most low-value mail. Formal entry means a licensed customs broker and a financial bond, requirements built for commercial shipments rather than a single patient’s monthly refill. That provision’s compliance date is October 22, 2026.
What often gets left out of the headlines: CBP built a specific alternative for exactly this situation. A new voluntary electronic process called Entry Type 13 began on September 22, 2026, giving eligible mail shipments — including ones regulated by the FDA — a lighter-weight informal entry option instead of full formal entry. It still requires a bond, and someone still has to handle the electronic filing (a foreign pharmacy, a broker, or in principle the patient themselves), but it’s a real, functioning mitigation path CBP created alongside the stricter rule, not a mere talking point.
Why Canadian Pharmacies Are Sounding the Alarm
Several Canadian and international pharmacies have told customers they expect the new requirements to seriously disrupt their ability to ship to individual U.S. patients, with at least one describing a near-total stop to shipments under the new process. Their concern is genuine and worth taking seriously — a compliance cost or bonding requirement that’s manageable for a large commercial shipment can be genuinely impractical when it’s attached to a single patient’s monthly prescription, and pharmacies serving thousands of individual U.S. customers may find the new process difficult to operate at that scale.
That said, this is the pharmacy industry’s own assessment of how the rule will affect their specific business model — not a government statement that every shipment will be stopped. No CBP or FDA announcement says Canadian prescription shipments are categorically banned starting October 22. What’s genuinely uncertain is how many pharmacies will find a workable path through formal entry or Entry Type 13, and how many will decide it’s not worth the cost and effort to keep serving U.S. patients at the volume they do today.
What Hasn’t Changed
It’s worth separating this customs change from FDA’s actual rules on personal drug importation, which are older and were already restrictive. In most circumstances, FDA has long taken the position that importing a foreign, U.S.-unapproved drug for personal use isn’t legal. Its personal-importation policy allows discretion in limited situations — typically requiring that the drug treats a serious condition without an available U.S. treatment, isn’t being marketed to American consumers, carries no unusual safety risk, and is limited to roughly a 90-day supply with appropriate medical documentation. A medication simply being cheaper in Canada has never, by itself, been a stated basis for that discretion.
In practice, this discretionary review has been applied loosely for decades — low-value personal parcels were rarely individually scrutinized. The October 22 customs change doesn’t rewrite FDA’s substantive standard; it changes the entry process around it, potentially making the existing (and already restrictive) FDA review more consistently applied than it has been in practice.
Who This Affects Most
Regardless of exactly how strictly the new rule ends up being enforced, the population most exposed is the one many Medicare-focused readers are already thinking about: people on fixed incomes managing chronic, lifelong conditions, for whom even a partial disruption to a lower-cost supply chain is a real problem, not an abstraction. Advocacy groups tracking this have reported a sharp spike in member concern once logistics companies began notifying pharmacies of the upcoming compliance date, and some patients have said they’d consider cutting doses or skipping medication rather than pay full U.S. prices.
What To Do If You Use Imported Medications
-
Don’t wait until October to act, but don’t panic either. Some Canadian pharmacies have already tightened order deadlines or stopped guaranteeing delivery close to the cutoff — but the actual outcome for any specific pharmacy or medication is still developing.
-
Ask your specific pharmacy directly how they plan to handle the change — whether through formal entry, the new Entry Type 13 process, or another arrangement — rather than assuming the worst based on a general news headline.
-
Check whether your Medicare Part D or Medicare Advantage plan’s formulary actually covers your medication, and at what tier. Formularies and manufacturer programs change yearly, and many people default to importing because a domestic price they saw once looked unaffordable.
-
Ask about Extra Help (the Part D Low-Income Subsidy) if cost has been the barrier — it can substantially reduce out-of-pocket costs, and many people who’d qualify have never applied.
-
Look into manufacturer patient assistance programs directly, especially for expensive brand-name drugs — many are income-based and don’t depend on your insurance plan at all.
-
If your current plan’s formulary doesn’t work for you, this fall’s Medicare Annual Enrollment Period (October 15 – December 7) is the window to actually change plans for 2027 coverage.
Questions Worth Asking
-
Has your specific pharmacy told you how they plan to handle shipments after October 22, or are you going on general news coverage alone?
-
Does your current Part D or Medicare Advantage plan actually cover the medication you’ve been importing, and if so, at what cost?
-
Have you checked whether you qualify for Extra Help or a manufacturer assistance program, rather than assuming your only options are the full U.S. price or a foreign pharmacy?
What To Do Next
If a prescription cost has been pushing you toward imported medications, let’s look at whether your current Medicare coverage — or a different plan available to you this Annual Enrollment Period — actually covers it at a price that works, regardless of how the customs situation plays out.
Questions? Call (800) 927-9326 or email
Prefer we reach out to you instead? Complete our Permission to Contact form and a licensed Gilman Agency agent will follow up.
Sources: U.S. Customs and Border Protection, “Indefinite Suspension of the De Minimis Exemption for Mail Shipments and New Postal Informal Entry Process,” 91 FR 37801 (June 24, 2026); U.S. Customs and Border Protection, “Test of the New Electronic Informal Entry Process for Mail” (Entry Type 13), 91 FR 38007 (June 24, 2026); U.S. Food and Drug Administration, Personal Importation guidance (fda.gov/importeddrugs); Xavier Martinez, “Americans Are About to Lose Access to Cheap Gray-Market Prescriptions From Canada,” The Wall Street Journal (September 22, 2026), for patient and industry perspective.
This article is for general educational purposes and reflects a regulatory change still developing as of publication. The practical impact on any specific pharmacy, medication, or patient may differ from general reporting — confirm directly with your pharmacy and prescriber. This is not medical advice; consult your prescriber before changing how or where you obtain any medication. This is not a recommendation regarding any specific plan or carrier. Consult a licensed advisor for guidance specific to your situation.
